aibioLakewood-Amedex holders approve share increase and reverse split authority
Tickers LABT
Stockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty.
Key facts
- Company
- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT)
- News type
- Listings
- Primary source
- Lakewood-Amedex Biotherapeutics Inc. 8-K (2026-09-29)
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) reported the results of its 2026 Annual Meeting of Stockholders, held on September 22, 2026, in an 8-K. As of the July 30, 2026 record date, 2,369,688 shares of common stock were outstanding and entitled to vote.
Stockholders approved an amendment to the articles of incorporation raising the number of authorized shares of common stock from 12,500,000 to 100,000,000. The vote was 927,022 for, 341,843 against and 711 abstaining.
They also authorized the board, at its sole discretion, to effect one or more reverse stock splits of the common stock at a cumulative ratio not to exceed one-for-twenty (1:20). That vote was 922,614 for, 333,546 against and 13,416 abstaining. A reverse split reduces the number of shares outstanding and raises the price per share.
Stockholders approved an amendment to the 2020 Equity Incentive Plan raising the number of shares issuable under it to 400,000. They elected Kelvin Cooper, Ph.D., Doug Manion, M.D., Leonard J. DeRoma and Joseph Tucker, Ph.D. as directors to serve until the 2027 annual meeting. They also ratified CBIZ CPAs P.C. as the independent registered public accounting firm.